期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

新辅助内分泌治疗在绝经后乳腺癌中的应用 被引量：6

暂未订购
导出
摘要 目的探讨新辅助内分泌治疗在绝经后激素受体阳性的乳腺癌患者的应用。方法回顾性分析40例绝经后ER和/或PR阳性的乳腺癌患者新辅助内分泌治疗的临床资料。结果40例患者中完全缓解2例,部分缓解27例,稳定8例,进展3例,总有效率为72.5%;来曲唑的疗效明显高于三苯氧胺,起效时间更短且不受CerbB-2的影响。结论绝经后激素受体阳性的乳腺癌患者应用新辅助内分泌治疗具有显著疗效,来曲唑疗效优于三苯氧胺。
作者 王利霞 施红旗 朱寿田
机构地区 浙江省金华市中心医院
出处 《实用肿瘤学杂志》 CAS 2008年第3期259-260,共2页 Practical Oncology Journal
关键词 新辅助内分泌治疗 绝经后 乳腺癌 来曲唑 三苯氧胺
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献10

二级参考文献36

  • 1Dixon JM, Anderson TJ, Miller WR. Neoadjuvant endocrine therapy of breast cancer : a surgical perspective. Eur J Cancer, 2002,38 ( 17 ) :2214-2221.
  • 2Hoff PM,Valero V, Buzdar AU, et al. Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy. Cancer,2000,88(9):2054-2060.
  • 3Dixon JM, Love CD, Bellamy CO, et al. Izetrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat,2001,66 ( 3 ) : 191-199.
  • 4Eiermann W, Paepke S, Appfelstaedt J,et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized doable-blind multicen|er study. Ann Oncol, 2001,12 ( 11 ) : 1527-1532.
  • 5Ellis MJ, Coop A, Singh B,et. al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB- 1 and/or ErbB-2 positive, estrogen receptor positive primary breast cancer: evidence from a phase Ⅲ randomized trial. J Clin Oncol,2001,19(18) :3808-3816.
  • 6Milla Santos A, Milla L, Cairo N, et al. Anastrozole as neoadjuvant therapy for patients with hormone- dependent, locally- advanced breast cancer. Anticancer Res,2004,24 (2C) : 1315-1318.
  • 7Dixon JM, Renshaw L, Bellamy C, et al. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin Cancer Res,2000,6(6) :2229-2235.
  • 8Miller WR, Dixon JM. Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. Cancer Control,2002,9(2 Suppl) :9-15.
  • 9Saji S, Hirose M, Toi M. Novel sensitizing agents: potential contribution of COX-2 inhibitor for endocrine therapy of breast cancer. Breast Cancer, 2004,11(2) :129-133.
  • 10Chow LW, Wong JL, Toi M. Celecoxib anti-aromatase neoadjuvant(CAAN) trial for locally advanced breast cancer: preliminary report. J Steroid Biochem Mol Biol, 2003,86(3-5 ) :443-447.

共引文献25

同被引文献58

引证文献6

二级引证文献35

实用肿瘤学杂志
2008年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部